Trials / Completed
CompletedNCT06670170
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
A PHASE 1, OPEN-LABEL, RANDOMIZED CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF TWO FORMULATIONS OF PF-07976016 ADMINISTERED ORALLY TO HEALTHY ADULT PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to measure and compare the amount of study drug in your blood after a single dose of two formulations of study drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07976016 Formulation A | PF-07976016; formulation A - current/reference |
| DRUG | PF-07976016 Formulation B | PF-07976016; Formulation B - new/test |
Timeline
- Start date
- 2024-11-05
- Primary completion
- 2024-12-24
- Completion
- 2025-01-17
- First posted
- 2024-11-01
- Last updated
- 2025-09-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06670170. Inclusion in this directory is not an endorsement.